Health Care [ 9/12 ] | Biotechnology [ 43/74 ]
NYSE MKT | Common Stock
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections.
The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments.
It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia.
In addition, the company develops NV-HHV-1, a skin cream for the treatment of Shingles rash, which has completed non-clinical pharmacology studies; oral drug with NV-HHV-1 as the active ingredient for the treatment of HSV-1 cold sores and HSV-2 genital ulcers; and other drug candidates in HIVCide program for the treatment of Dengue and Ebola virus, as well as provides Nanoviricide platform technology to treat various types of viruses.
NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Dec 3, 25 | -0.14 Increased by +40.79% | -0.18 Increased by +25.00% |
| Sep 3, 25 | -0.12 Increased by +36.84% | -0.20 Increased by +40.00% |
| May 12, 25 | -0.14 Increased by +13.56% | -0.19 Increased by +27.21% |
| Feb 12, 25 | -0.14 Increased by +22.72% | -0.18 Increased by +22.72% |
| Nov 12, 24 | -0.23 Decreased by -52.00% | -0.17 Decreased by -34.12% |
| Aug 28, 24 | -0.19 Increased by +37.75% | -0.31 Increased by +38.71% |
| May 15, 24 | -0.16 Decreased by -9.36% | -0.19 Increased by +15.79% |
| Feb 14, 24 | -0.18 Decreased by -20.00% | -0.19 Increased by +5.26% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 0.00 Decreased by N/A% | -1.79 M Increased by +42.91% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -2.10 M Increased by +11.04% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -2.22 M Decreased by -19.54% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by N/A% | -2.03 M Increased by +4.13% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -3.13 M Decreased by -58.82% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -2.36 M Increased by +34.01% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -1.85 M Decreased by -8.91% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -2.11 M Decreased by -21.19% | Decreased by N/A% Decreased by N/A% |